The effect of inflammatory scores on the prognosis of malignant mesothelioma

Abstract

Aims: Malignant mesothelioma (MM) is a rare cancer with a poor prognosis that is frequently detected late in the disease's progression. The purpose of our sudy was to contribute to the literature by investigating how inflammation indices such as neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), lymphocyte/monocyte ratio (LMR), prognostic nutritional index (PNI), systemic inflammation response index (SIRI), and HALP scores affect disease progression and prognosis in patients with MM. Methods: This study retrospectively examined 85 patients pathologically diagnosed with malignant pleural and peritoneal mesothelioma. NLR, PLR, LMR, PNI, SIRI, and HALP scores of the patients were calculated. Results: The area under the curve (AUC) values obtained by ROC analysis are NLR (0.65), PLR (0.67), LMR (0.66), PNI (0.64), SIRI (0.66), and HALP (0.77). The cut-off values were as follows: NLR (3.2), PLR (168.5), PNI (35.2), LMR (2.5), SIRI (2.2) and HALP (22.8). In multivariate analysis, being inoperable was found to be associated with lower survival, while receiving chemotherapy and high PNI value were found to be associated with higher survival (p<0.05). Conclusion: In our study, patients with high PNI had longer median survival time. This score can serve as a simple and useful scoring system for predicting the prognosis of malignant pleural mesothelioma in clinical practice.

Keywords

• Inflammation indices
• malignant mesothelioma
• prognostic nutritional index

Ethical Statement

The writers are responsible for all aspects of the writing, including ensuring that any concerns about the work’s quality or credibility are thoroughly investigated and resolved. University of Health Sciences Atatürk Sanatorium Training and Research Hospital (Ankara, Turkey) Ethics Committee approved this study (No:2024-BÇEK/96). This research was carried out in conjunction with the Helsinki Declaration (as revised in 2013).

References

1. Jain M, Crites MK, Rich P, Bajantri B. Malignant pleural mesothelioma: a comprehensive review. J Clin Med. 2024;13(19):5837. doi:10.3390/jcm 13195837
2. Mutlu E, Inanc M. Prognostic significance of inflammation scores in malignant mesothelioma. Eur Rev Med Pharmacol Sci. 2024;28(6):2340-2350. doi:10.26355/eurrev_202403_35741
3. Yamagishi T, Fujimoto N, Nishi H, et al. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma. Lung Cancer. 2015;90(1):111-117. doi:10.1016/j.lungcan. 2015.07.014
4. Ozyurek BA, Ozdemirel TS, Ozden SB, et al. Does advanced lung inflammation index (ALI) have prognostic significance in metastatic non-small cell lung cancer? Clin Respir J. 2018;12(6):2013-2019. doi:10. 1111/crj.12768
5. Karakaya S, Karadağ İ, Dogan M et al. Potential novel prognostic factors in malign mesothelioma: systemic inflammatory indices (SII) & albumin-to-globulin ratio (AGR). Acta Haematol Oncol Turc. 2021; 54(3):358-366. doi:10.5505/aot.2021.58815
6. Gu X, Sun S, Gao XS, et al. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients. Sci Rep. 2016;6(1):23893.
7. Gong C, Yu X, Zhang W, et al. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles. J Nanobiotechnology. 2021;19(1):58. doi:10.1186/s12951-021-00805-8
8. Chen XL, Xue L, Wang W, et al. Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte and platelet in patients with gastric carcinoma: a retrospective cohort study. Oncotarget. 2015;6(38):41370-41382. doi:10.18632/oncotarget.5629

9. Kılınç CY, Gürsan O, Acan A, Gultac E. Prognostic nutritional index predicts perioperative adverse events in patients undergoing hemiarthroplasty after a hip fracture. J Exp Clin Med. 2022;39(1):24-27.
10. Vogl M, Rosenmayr A, Bohanes T, et al. Biomarkers for malignant pleural mesothelioma-a novel view on inflammation. Cancers (Basel). 2021;13(4):658–658. doi:10.3390/cancers13040658
11. Chen N, Liu S, Huang L, et al. Prognostic significance of neutrophil- to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysis. Oncotarget. 2017;8(34):57460-57469.
12. Yin W, Zheng G, Yang K, Song H, Liang Y. Analysis of prognostic factors of patients with malignant peritoneal mesothelioma. World J Surg Oncol. 2018;16(1):44. doi: 10.1186/s12957-018-1350-5
13. Alpert N, van Gerwen M,Taioli E. Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted/ banned asbestos use. Transl Lung Cancer Res. 2020;9(suppl 1):S28-S38.
14. Chen T, Sun X-M, Wu L. High time for complete ban on asbestos use in developing countries. JAMA Oncol. 2019;5(6):779-780.
15. Taioli E, Wolf A, Alpert N, Rosenthal D, Flores R. Malignant pleural mesothelioma characteristics and outcomes: a SEER-Medicare analysis. J Surg Oncol. 2023;128(1):134-141. doi:10.1002/jso.27243
16. Tural Onur S, Sokucu SN, Dalar L, et al. Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio reliable parameters as prognostic indicators in malignant mesothelioma? Ther Clin Risk Manag. 2016;12: 651-656.
17. Cihan YB, Ozturk A, Mutlu H. Relationship between prognosis and neutrophil: lymphocyte and platelet lymphocyte ratios in patients with malignant pleural mesotheliomas. Asian Pac J Cancer Prev. 2014;15(5): 2061-2067. doi:10.7314/apjcp.2014.15.5.2061
18. Yao ZH, Tian GY, Yang SX, et al. Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma. Tumour Biol. 2014;35(7):6839-6845. doi:10.1007/s13277-014-1938-5
19. Yao ZH, Tian GY, Wan YY, et al. Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma. J Cancer Res Clin Oncol. 2013;139(12):2117-2123. doi:10.1007/s00432-013-1523-0
20. Ebinç S, Oruç Z, Kalkan Z, et al. Prognostic factors and the prognostic role of inflammation indices in malignant pleural mesothelioma. Turk Gogus Kalp Damar Cerrahisi Derg. 2023;31(1):105-115.
21. Dogan M, Utkan G, Hocazade C, et al. The clinicopathological characteristics with long-term outcomes in malignant mesothelioma. Med Oncol. 2014; 31(10): 232.